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ABSTRACT
Impact of Heart-Rate Variability Biofeedback on Major Depression Disorder
in Resting-State fMRI
Hiu Wai Caldwell
Department of Psychology, BYU
Doctor of Philosophy
Major depressive disorder (MDD) is one of the most common psychiatric illnesses and
causes significant disturbances in daily functioning. Research on heart-rate variability (HRV)
biofeedback training suggests that HRV is an efficacious adjunct to psychotherapy in reducing
depressive symptoms. The purpose of this study was to examine neurological changes in
depressed individuals who were randomized to either a psychotherapy plus HRV biofeedback
training or to a treatment as usual group. A control group with no history of depression was also
studied. We collected psychological, physiological, and imaging data from 30 participants (10 in
an experimental group, 10 in a treatment as usual group, and the other 10 in a healthy control
group) at baseline and follow-up. Regions of interest (ROIs) included anterior cingulate cortex,
hippocampus, and amygdala. Participants from the experimental group went through 5 weekly
HRV trainings in conjunction with traditional psychotherapy approaches. The treatment as usual
group only received psychotherapy. The healthy controls did not receive any HRV training or
therapy services. Overall, we found significant improvements in the experimental group’s
depression score, overall distress level, and HRV measurements relative to the TAU and control
groups. However, we did not find significant HRV and resting-state connectivity group
differences among experimental group relative to healthy controls. Together, results suggest that
HRV training helps to reduce depressed participants’ overall distress level and depressive
symptoms. However, findings do not show any changes in participants’ imaging data. These
findings serve as pilot data on literature related to HRV biofeedback training in a depressed
population.
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1

Impact of Heart-Rate Variability Biofeedback
on Major Depression Disorder in Resting-State fMRI

Major depressive disorder (MDD) is one of the most common psychiatric illnesses
(Waraich, Goldner, Somers, & Hsu, 2004). A systematic review reported that MDD has a 12month prevalence of 3.7% in which women are twice as vulnerable compared to men (Ferrari et
al., 2013). Individuals with MDD experience significant emotional distress, such as anhedonia,
feelings of worthlessness, and inappropriate guilt, which cause dysfunction in daily functioning.
Moreover, empirical evidence suggests that there is approximately 16% - 40% lifetime suicide
attempt in MDD (Oquendo, Currier, & Mann, 2006). In general, researchers examine MDD from
different perspectives, such as genetic (Elder & Mosack, 2011), biochemical (Gao & Bao, 2011),
cognitive (Ciesla, Felton, & Roberts, 2011), sociocultural (Holzel, Harter, Reese, & Kriston,
2011), and neuroanatomical models (Campbell, Marriott, Nahmias, & MacQueen, 2004).
Neuroanatomical models of depression have not yet been fully investigated.
With advancing technology, researchers are able to investigate the association between
depression and its neurobiological abnormalities as well as develop new interventions. Research
findings indicate that individuals suffering from depression have structural and functional
abnormalities in the anterior cingulate cortex (ACC), hippocampus, and amygdala (Drevets,
Bogers, & Raichle, 2002; Firbank et al., 2005; Gunning et al., 2009; Milne, MacQueen, & Hall,
2012). Pharmacological and psychotherapeutic interventions are typically used to treat
depression (Cuijpers, Huibers, Ebert, Koole, & Andersson, 2013; Cuijpers, van Straten, van
Oppen, & Andersson, 2008). Newer treatment approaches are also being developed that are used
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as adjuncts to standard treatment. One of the adjunct therapy options is heart-rate variability
(HRV) biofeedback training (Tonhajzerova et al., 2009).
HRV refers to the unceasing transition between sympathetic and parasympathetic
activities resulting in variations in heartbeat. Previous research suggests that individuals’ HRV
reaches its highest amplitude through breathing at a resonance frequency (Hassett et al., 2007).
Maximized HRV has been associated with positive health outcome (Cohen & Benjamin, 2006;
Karavidas et al., 2007; Nolan et al., 2005). Reduced HRV has been associated with increased
depression symptoms (Glaser & Glaser, 2002). Recent evidence indicates that HRV biofeedback
training improves depressed patients’ HRV which links with better emotion control (Apelbaum,
2001; Appelhans & Luecken, 2006; Grippo & Johnson, 2002; Karavidas et al., 2007). Depressed
individuals report lower levels of depression symptoms after employing HRV biofeedback
technique (Siepmann, Aykac, Unterdorfer, Petrowski, & Mueck-Weymann, 2008; Uhlmann &
Froscher, 2001). Details relationship between HRV and depression was discussed below. Overall,
this research project sought to examine the effects of HRV training on depressive symptoms and
connectivity between the ACC, hippocampus, and amygdala.
Depression and Brain Functioning
Numerous studies have been devoted to investigating the relationship between depression,
brain anatomy, and brain functioning. Converging findings in depressed individuals indicate
disrupted frontal lobe function and limbic system activity (Anand et al., 2005; Ketter et al., 2001).
To be specific, brain-imaging techniques have shown hypermetabolism in medial prefrontal
cortex (Mayberg, 2003) and decreased functional connectivity between prefrontal cortex and
anterior cingulate cortex (Aizenstein et al., 2009) among people with major depressive disorder.
Furthermore, similar studies reported volume reduction and abnormal elevations of resting

3

cerebral blood flow in limbic structures, such as hippocampus and amygdala (Drevets, 2001;
Liotti & Mayberg, 2001; Mervaala et al., 2000) In sum, anomalous activities in the ACC regions
and subcortical system, such as amygdala and hippocampus have been associated with irregular
emotion processing and regulation (Bremner, Vythilingam, Vermetten, Vaccarino, & Charney,
2004; Fitzgerald, Laird, Maller, & Daskalakis, 2008; Heinz et al., 2007; Kupfer, Frank, &
Phillips, 2012).
In addition to the findings stated above, researchers also report aberrant resting-state
functional connectivity among individuals with major depressive disorder from ACC regions to
subcortical structures (Anand et al., 2005; Greicius et al., 2007). Resting-state functional
connectivity measures correlations in the blood-oxygen-level-dependent (BOLD) signal between
brain regions in a given time series. This methodology has been well established to investigate
the integration, changes in brain networks, and their connectivity when no task is performed
(Raichle & Mintun, 2006). For example, a recent study on resting-state fMRI found decreasing
connectivity between ACC and amygdala in depressed patients compared to a healthy control
group (Anand, Li, Wang, Lowe, & Dzemidzic, 2009). The decreased corticolimbic connectivity
suggests a trait abnormality in depressive disorder. Furthermore, another study revealed that
nonrefractory major depressive patients have reduced connectivity in ACC, hippocampus,
amygdala, and prefrontal cortex (Lui et al., 2011). This result indicates a distinct functional
deficit in MDD patients’ brain networks. Overall, findings from Anand et al. (2009) and Lui et al.
(2011) suggest that decreased corticolimbic connectivity is associated with reduced mood
regulation ability.
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Depression Treatment
Depression is characterized by feelings of sadness and a lack of desire to pursue usual
activities. Depressed individuals are relatively less active, hold negative views of themselves,
and in high risk of attempting suicide (Bolton, Belik, Enns, Cox, & Sareen, 2008). Due to the
adverse effects of depression, a large body of research has been conducted in an attempt to reach
effective treatment outcomes for MDD. In light of existing evidence, most treatment outcome
studies have focused on antidepressant medications and psychotherapies (Cipriani et al., 2009;
Cuijpers, Dekker, Hollon, & Andersson, 2009; Cuijpers et al., 2008; Jakobsen et al., 2012;
Zimovetz, Wolowacz, Classi, & Birt, 2012).
Despite the high usage of antidepressants, findings from several studies suggest that only
a third to a half of patients find antidepressants to be effective (Pigott, Leventhal, Alter, & Boren,
2010; Rush et al., 2006). After an inadequate response to antidepressant treatment is found, the
most common pharmacological strategies are switching antidepressant medication and
combining antidepressants with psychotherapy (Garcia-Toro, Medina, Galan, Gonzalez, &
Maurino, 2012; Papakostas, 2009). Effective treatment approaches toward depression include
cognitive therapy (Jakobsen, Hansen, Storebo, Simonsen, & Gluud, 2011; Wampold, Minami,
Baskin, & Tierney, 2002) and cognitive behavior therapy (CBT; Butler, Chapman, Forman, &
Beck, 2006; Haby, Tonge, Littlefield, Carter, & Vos, 2004). Cognitive therapy focuses on
recognizing and changing maladaptive cognitive process (Beck, Rush, Shaw, & Emery, 1979).
CBT includes a number of behavioral techniques that encourage depressed individuals try
modify behaviors in addition to the cognitive component. Beside the above two therapies,
interpersonal therapy (Cuijpers et al., 2011; van Hees, Rotter, Ellermann, & Evers, 2013) is also
found to be helpful in treating depression. Interpersonal therapy emphasizes on exploring
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individual’s relationship with others and developing social skills for new roles’ transition
(Weissman & Markowitz, 2002). The combination of psychopharmacology and psychological
treatments is effective compared to treatment with pharmacotherapy alone (Friedman et al., 2004;
Pampallona, Bollini, Tibaldi, Kupelnick, & Munizza, 2004) or psychotherapy alone (De Maat,
Dekker, Schoevers, & de Jonghe, 2007).
In addition to pharmacology and psychotherapy, a sizeable number of adjunct therapy
options have been studied in an attempt to help elucidate treatment effectiveness involved in
MDD. Those adjunct options consist of, for example, the use of nutrients (Amr, El-Mogy, Shams,
Vieira, & Lakhan, 2013; Gertsik, Poland, Bresee, & Rapaport, 2012) and real-time
psychophysiological self-regulation, such as neurofeedback (Linden et al., 2012) and HRV
biofeedback training (Tonhajzerova et al., 2009).
HRV Biofeedback
HRV is a function of vagal nerve, the nerve that is associated with parasympathetic
functioning, control of heart rate (HR). Sympathetic activity such as inhalation inhibits vagal
nerve stimulation and results in increasing heart rate (Beevers, Ellis, & Reid, 2011).
Parasympathetic activity such as exhalation excites vagal nerve function and results in
decreasing heart rate (Lehrer et al., 2013). In a healthy individual, there are large differences in
heart rate as people breathe in and breathe out. Many people assume that if someone has a heart
rate of 70 beats per minute, that the heart beats constantly at that rate throughout each minute.
This is not the case, however. Rather, heart rate is constantly fluctuating as a function of
breathing (Lehrer et al., 2013; Shaffer & Venner, 2013) and the unceasing transition between
sympathetic and parasympathetic activities results in HRV. In other words, HRV refers to the
variations in amplitude between consecutive heartbeats oscillations (Shaffer & Venner, 2013).
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When individuals’ heart rate and breathing are completely in sync, they are breathing at
their optimal breathing rate which results in higher amplitude of HR oscillations and leads to
higher HRV (Hassett et al., 2007; Vaschillo, Lehrer, Rishe, & Konstantinov, 2002). In fact, the
larger the fluctuation in heart rate, the healthier is the heart (Del Pozo, Gevirtz, Scher, &
Guarneri, 2004). Empirical evidences suggest that increasing HRV has been associated with
positive health outcomes and well-being (Cohen & Benjamin, 2006; Del Pozo et al., 2004;
Karavidas et al., 2007; Nolan et al., 2005; Swanson et al., 2009). Various methods have been
employed in increasing individuals’ HRV. One of the techniques is optimal breathing HRV
biofeedback (Prinsloo, Derman, Lambert, & Rauch, 2013; Siepmann, Aykac, Unterdorfer,
Petrowski, & Mueck-Weymann, 2008). This breathing technique teaches individuals to breathe
completely in phase with their heartbeat so that the amplitude of heart rate oscillations can be
maximized.
To date, findings in HRV biofeedback training demonstrate that such techniques lead to
positive outcomes in a variety of health problems. For examples, after receiving HRV
biofeedback training, participants show significant improvement in cardiac morbidity (Del Pozo
et al., 2004), pulmonary function (Lehrer et al., 2003), and exercise tolerance (Swanson et al.,
2009). Indeed, upon receiving HRV biofeedback training, not only patients with cardiovascular
and respiratory problems benefit from it (Giardino, Chan, & Borson, 2004; Nolan et al., 2005;
Palomba et al., 2011), but also individuals suffering from chronic pain (Hallman, Olsson, von
Scheele, Melin, & Lyskov, 2011), headache (Blume, Brockman, & Breuner, 2012; Nestoriuc,
Martin, Rief, & Andrasik, 2008), anxiety (Cohen & Benjamin, 2006; Ratanasiripong, Sverduk,
Prince, & Hayashino, 2012) and depressive disorders (Karavidas et al., 2007).
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HRV Biofeedback and Depression
Empirical findings suggest that HRV and emotion regulation play an important role in
depression (Aldao, Nolen-Hoeksema, & Schweizer, 2010; Brockmeyer et al., 2012; Garnefski &
Kraaij, 2006; Siepmann et al., 2008). Higher HRV values correlate with better emotion
regulation and expression (Appelhans & Luecken, 2006; Segerstrom & Nes, 2007). The
mechanism between HRV and emotion regulation lies in flexibility of the autonomic nervous
system (ANS; Quintana, Guastella, Outhred, Hickie, & Kemp, 2012). In general, emotion
regulation is related to physiological arousal. The sympathetic nervous system (SNS) is more
active during high arousal states whereas the parasympathetic nervous system (PNS) is more
active during rest and relaxation. The transition between SNS and PNS can be seen in HRV,
which reflects the alteration of emotional and physiological changes.
Depressed individuals have impaired HRV relative to healthy control subjects (Kemp,
Quintana, Felmingham, Matthews, & Jelinek, 2012; Patron et al., 2012). In fact, reduced HRV is
correlated with increased depressive symptoms (Carney & Freedland, 2008; Champaneri, Wand,
Malhotra, Casagrande, & Golden, 2010; Kemp et al., 2012). After receiving biofeedback training,
individuals with depression demonstrated higher levels of HRV and reported decreased level of
depression symptoms (Karavidas et al., 2007; Siepmann et al., 2008; Uhlmann & Froscher,
2001). Thus, research findings suggest that HRV appears to be an effective adjunct treatment for
depression.
The Present Study
Previous studies have only explored the impact of HRV biofeedback training on
depressed patients (Apelbaum, 2001; Segerstrom & Nes, 2007), and their brain activity
separately (Ketter et al., 2001; Liotti & Mayberg, 2001). While incorporating HRV biofeedback
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into treatment for depression yields favorable outcomes (Beckham, Greene, & Meltzer-Brody,
2013; Patron et al., 2013), relevant changes in brain areas have not yet been examined in detail.
Therefore, this study aimed to examine the impact of HRV biofeedback training on depression
symptoms severity, and resting-state connectivity in individuals with major depression. Specially,
the connectivity between the ACC, hippocampus, and amygdala were examined.
Resting-state fMRI was chosen in this study for three main reasons. First and foremost,
resting-state fMRI allowed us to examine brain integration and connectivity. Additionally,
resting-state fMRI required minimal compliance from the participants – they laid still on the
scanner bed with no tasks assigning to them. Errors from movement were reduced in the process
of data collection. Also, according to Fox and Raichle (2007) resting-state fMRI allowed more
direct comparison between groups.
The regions of interest (ROIs) in this study were the ACC, hippocampus, and amygdala.
These three areas have received particular focus in depression research in a series of related
studies (Anand et al., 2005; Drevets, 2001; Ketter et al., 2001). A convergence of research
findings indicate that dysfunction within these ROIs contributes to maladaptive emotion
regulation (Anand et al., 2009; Anand et al., 2005; Cullen et al., 2009). Therefore, this study
adopted this research strategy and looked at connectivity between these three ROIs.
Hypotheses. Since both participants from the experimental group (Exp) and the treatment
as usual group (TAU) had MDD, it was hypothesized that before HRV training, there would be
no significant differences between these two groups in their HRV, severity of depression
symptoms, overall distress level, and resting-state connectivity across ROIs. It was also
hypothesized that there would be significant differences between the depressed participants (Exp
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and TAU groups) and healthy control group (Ch) in their HRV, severity of depression symptoms,
overall distress level, and resting-state connectivity across ROIs before HRV training.
After participants from the Exp group received HRV biofeedback training, it was
hypothesized that they would show significantly increased HRV and decreased depression
symptoms and overall distress level in comparison to their baseline measurement and with the
TAU group. In contrast, it was expected that there would be no differences between the Exp and
Ch groups in their HRV, depression symptoms, and overall distress level. In addition, it was also
hypothesized that after finishing HRV biofeedback training, the Exp group would show
significantly higher resting-state fMRI connectivity between the ROIs in comparison with their
baseline measurement and the TAU group. Studies on combining fMRI demonstrated that
depressed individuals show less connectivity between the cingulate cortex and subcortical
structures (Anand et al., 2009; Lui et al., 2011; Napadow et al., 2008). Since HRV biofeedback
has been shown to be correlated with improving emotion regulation (Appelhans & Luecken,
2006), our study, therefore, hypothesized that there would be a significant change in the Exp
group’s resting-state fMRI connectivity between the ROIs before and after the HRV training.
Furthermore, it was hypothesized that after receiving HRV biofeedback training, there
would be no significant differences between the Exp and Ch in the follow-up ROIs’ resting-state
fMRI connectivity. Empirical evidence suggests that depressed individuals have lower
connectivity between anterior cingulate cortex and subcortical structures than healthy population
(Anand et al., 2005). Therefore, we anticipated there would be a significant difference between
the Exp and Ch group in their baseline connectivity measurement. Once again, since HRV
techniques have been associated with increasing mood regulation (Appelhans & Luecken, 2006),
the presented study, therefore, hypothesized that there would be a significant change in the Exp’s
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follow-up connectivity measure in which the gap between Exp and Ch group would shift to a
non-significant level.
Based on the hypotheses above, dependent variables in this study were the total score of
the severity of depression symptoms from the Beck Depression Inventory-II (BDI-II; Beck, Steer,
& Brown, 1996) and the total score of participants’ overall distress level from the Outcome
Questionnaire (OQ45; Lambert, Lunnen, Umphress, Hansen, & Burlingame, 1994). Aside from
the above two measures, this study also used HRV physiological variables and connectivity
between the ROIs as dependent variables. Abnormal activities in ACC, hippocampus, and
amygdala have been found across studies of depression (Anand et al., 2009; Anand et al., 2005;
Cullen et al., 2009). Therefore, this study sought to examine how biofeedback training has an
impact on these three ROI’s in depressed individuals.
The independent variable in this study, similar to Siepmann et al. (2008), was exposure to
HRV biofeedback to Exp group versus TAU group in depressed individuals seeking therapy at
the BYU counseling center. A healthy group of college students (no depression) was also used as
a healthy control group. A slight modification was made in this study that all of the follow-up
measurements (HRV, depression symptoms measurements, and brain scans) were done within 2
weeks upon completion of the biofeedback training. Siepmann et al. (2008) measured HRV and
severity of depression symptoms in their follow-up study, the presented study added a
component on fMRI imaging in it.
Why was this study unique? The presented study was unique because it served as a
pilot study examining the neurological changes in depressed individuals who underwent HRV
biofeedback training. While many studies have examined the association between depression and
neurological change and few studies have explored the effects of biofeedback training on
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depression, no research has investigated these three components together. Therefore, the
presented was unique. Also, this study provided additional evidence of the efficacy of
biofeedback training for depression treatment.

Participants

Methods

A total of 32 female individuals were recruited. Participation was completely voluntary.
Exclusion criteria included an age less than 18 or over 25 years, use of vasoactive medications,
cardiovascular disease, alcohol or drug abuse, any physiological or neurological disorders,
history of electroconvulsive therapy, head injury, and MRI incompatibility. Participants were
compensated $20 for each MRI scanning session and $10 for each biofeedback session. IRB
approval was approved prior to beginning the study.
Within the 32 participants, a total of 21 individuals with MDD were recruited through
Brigham Young University (BYU) Counseling Center consecutively. One participant with MDD
was excluded in the study due to equipment errors. In total, 20 participants with MDD remained
in the study. All of them met diagnostic criteria for MDD, with five reporting a history of
depressive symptoms during their teen years. One of the MDD participants reported current use
of medication (Prozac); however, she was in the process of weaning off this medication. Overall,
half of the MDD participants was randomly assigned into the Exp group (n = 10) whereas
participants received both HRV biofeedback training and treatment as usual for MDD. The other
half of the group (n = 10) served as the TAU group where they only received treatment as usual
for MDD without biofeedback training. Another 11 healthy individuals were recruited through
BYU campus as the Ch group. One participant from the Ch group was excluded due to equipment
errors. In total, 10 participants remained in the Ch group. None of them met criteria for any
psychiatric disorders or reported medication use. Thus, final groups submitted for data analyses
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consisted of 20 MDD participants and 10 healthy control participants. These groups did not
differ by age (Exp ages M = 20.09, SD = 1.81; TAU ages M = 20.20, SD = 1.47; Ch ages M =
20.64, SD = 1.29, see Table 1).
Psychological Measures
A structured clinical interview, namely the MINI International Neuropsychiatric
Interview (M.I.N.I.; Sheehan et al., 1998) was used in this study. The M.I.N.I is one of the most
widely used clinical structured diagnostic interview instrument employed by mental health
professionals with good internal consistency – Cronbach’s alpha equals to .66 (Sheehan et al.,
1998). Thus, this study used the M.I.N.I in recruitment stage to ensure all individuals in the Exp
group and TAU group met criteria for MDD, and all participants from the Ch group did not meet
criteria for any disorders list on M.I.N.I.
A self-ratings depression scale, the BDI-II (Beck et al., 1996) was used to examine the
severity of depression symptoms across all participants. The BDI-II consisted of 21 groups of
statements where participants picked one statement in each group that best described their
feeling during the past two weeks. The total score of BDI-II was 63 with 4 levels of cutoff scores.
A total score between 0-13 indicated “minimal” level of depression, score between 14-19
indicated “mild” level of depression, score between 20-18 indicated “moderate” level of
depression, and score between 29-63 indicated “severe” level of depression. The BDI-II has
internal consistency ranges from .87 to .93 (Titov et al., 2011), one-week test-retest reliability
at .93 (Beck et al., 1996), and cronbach's alpha at .93 level among college students population
(Poole, Bramwell, & Murphy, 2006). Its reliability and validity have been supported (Roelofs et
al., 2013).
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A 45 items self-report measure for overall degree of disturbance in the course of
treatment, the OQ45 (Lambert et al., 1994) was used to keep track of changing in participants’
overall distress level. Each item in the OQ45 was scored on a 5-point Liket scale, from “0” never
to “4” almost always. The total score of OQ45 was 150 with a cutoff score 63. A total score at or
greater than 63 indicated possible clinically significant distress. Furthermore, this level of
distress suggested that individuals were admitting a large number of distress symptoms in their
general quality of life (Hanson & Merker, 2005). OQ45 has internal consistency ranges from .7
to .93 and test-retest reliability .78 to .84 (Hanson & Merker, 2005).
Physiological Measures
Physiological data were recorded through a biofeedback system (J&J Engineering,
Poulsbo, WA). Quantification of variability that allowed us to assess how much or how little
HRV was occurring included the following variables: HR, one time-domain measure: standard
deviation of normal-to-normal intervals (SDNN) between adjacent heartbeat, two frequency
domain measures: high frequency (HF) and low frequency (LF), and the ratio between LF and
HF (LF/HF). SDNN referred to the amount of variability in heartbeat interval. It built from
corresponding mean value of all the 5-minute of heartbeat interval standard deviations across
time. Higher value in SDNN was associated with better health outcome. This time-domain
measure was a common measure in psychophysiology which assessing HRV (DeGiorgio et al.,
2010). HF HRV reflected parasympathetic activity; its value ranged between 0.15 to 0.40 Hz
(Karavidas et al., 2007; Kemp et al., 2012). The higher the high frequency value, the more
dominant is the parasympathetic system. LF HRV influenced by both the sympathetic and
parasympathetic systems; its value ranged from 0.05 to 0.15 Hz (Karavidas et al., 2007). Lower
low frequency values reflected greater influence from the sympathetic system. Since activity in
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both the sympathetic and parasympathetic systems were almost always presented together, the
LF/HF ratio provides an index for automatic balance between the two systems. This ratio also
carried information about sympatho-vagal balance; its value ranged from 1.1 to 11.6 (Nunan,
Sandercock, & Brodie, 2010).
Images Parameters
MRI data were collected on a Siemens 3 Tesla Tim MAGNETOM® Trio scanner
(Erlangen, German) using a 12-channel head coil at the Brigham Young University MRI
Research Facility (Provo, UT). Structural images were acquired using a standard T1-weighted
MPRAGE sequence with the following parameters: 176 slices; TR = 1900 ms; TE = 2.26 ms;
flip angle = 9°; field of view = 250 mm; slice thickness = 1 mm; voxel resolution = 1 ×1 ×1 mm;
1 average.
Functional images were acquired using a gradient-echo echoplanar, T2*-weighted pulse
sequence with the following parameters: 39 interleaved slices; TR = 2000 ms; TE = 28 ms; flip
angle 90°; field of view = 192 mm; slice thickness = 3 mm; voxel resolution = 3 × 3 × 3 mm;
measurements = 180. The first 3 TRs acquired were discarded to allow for T1 stabilization.
Procedure
All participants were recruited through the BYU campus and Counseling Center.
Informed consent was given prior to clinical interview. After potential participants signed the
informed consent, the M.I.N.I was administered. In accordance with the purpose of this study as
indicated above, all participants who met criteria for MDD were randomized into either the Exp
or TAU group. Individuals without any psychopathology were assigned into the Ch group. All
participants from the 3 groups were scheduled for the baseline brain scans and HRV
measurements.

15

Baseline measurement. Each participant was asked to abstain from exercising,
consuming caffeinated and tobacco products for 3 hours before testing (Gianaros et al., 2005).
All participants went to the BYU MRI Research Facility for a baseline resting-state MRI
measurement. Upon arrival, participants filled out a consent form specifically for MRI
procedures. A verbal description and a screening form designed specifically for the MRI
Research Facility were administrated to the participants. Participants were led to the fMRI
scanner room and stayed on the scanner bed quietly for approximately 29 minutes. All
participants were instructed to stay awake with eyes closed. They wore earplugs and were
positioned carefully in the 12-channel receive-only head coil with comfortable support. The first
3 dummy scans were discarded to allow magnet stabilization. The study duration from arrival
until they left the scanner room was approximately 45 minutes. After the scanning, participants’
baseline HRV was measured at the BYU Counseling Center, which was about 5 minutes away
from the MRI Facility.
At the BYU Counseling Center, participants were given a verbal explanation on the
procedure of the HRV measurement. An online survey which includes BDI-II, OQ45, and
demographic information was administrated. After that, a respiration belt was attached directly
over participant’s belly button for respiration data. An electrocardiography (ECG) electrode was
placed on each side of the wrist for ECG signals. A ground electrode was put on the left side of
the wrist, right above the ECG electrode. After all the sensors were hooked up, participants
breathed with their normal day-to-day breathing rate for 10 minutes as a baseline measurement.
After the baseline recording, all participants from the Exp group received their first HRV
training session. The TAU and Ch groups were scheduled to come back for follow-up
measurements.
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1st HRV training. This training session occurs on the same day, right after the HRV
baseline measurement. The purpose of the first training session was to demonstrate and teach
abdominal breathing. For more detail on the procedures see Lehrer et al. (2013). In brief,
participants learned diaphragmatic breathing. Participants practiced diaphragmatic breathing for
20 minutes. This breathing technique sat the stage for the following 4-week HRV training
sessions. Upon finishing the first training session, participants were scheduled for their second
visit and reminded to practice abdomen breathing 15 to 20 minutes a day for 4 to 5 times a week.
Additionally, participants received a weekly e-mail reminding them to practice and their weekly
appointment. Of note, the baseline HRV measurement and all of the following HRV training
sessions lasted approximately 30 to 45 minutes each.
2nd HRV training. The purpose of the second training session was to determine
participants’ optimal breathing rate, i.e. the rate that got participants into the greatest oscillations
of HR. At the beginning of this training session, all participants were instructed to do
diaphragmatic breathing for 3 minutes then breathed at different rates, from 6.5 down to 4.5
breathes per minute (E. G. Vaschillo, Vaschillo, & Lehrer, 2006) with a change of .5 stepped
down each time. Each rate of breathing lasted for 2 minutes and HRV data was recorded for each
breathing rate. A visual pacer on a computer screen guided participants at each respiratory rate.
Participants’ optimal breathing rate was determined by the highest LF value, which was
generated from the J&J program. Once participants’ optimal breathing rate was determined, they
were instructed to practice with a visual pacer corresponds to their target optimal breathing rate
for another 3 minutes. Upon completion, participants were scheduled for three weekly 20
minutes HRV training sessions. They were also inculcated to practice 4 to 5 times a week for
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three weeks, between 15 to 20 minutes a day by using visual guides that could be downloaded
from the internet for free.
3rd, 4th and 5th HRV training. These three training sessions aimed to fine tune and
target participants’ optimal breathing rate. Participants practiced their optimal breathing rate and
breathed in phase with their heart rate for 20 minutes on each of the visit. A follow-up
appointment was scheduled upon completion of the 5th training session.
Follow-up measurement. All participants first received follow-up resting-state brain
scans before the HRV follow-up measurement. The follow-up brain imaging appointment took
approximately 45 minutes. Correspond with the baseline brain imaging appointment, a verbal
description and screening form regarding the MRI scanner were given, followed by a structural,
functional, and diffusion tensor imaging brain scan. After the follow-up scans, all participants
went to the BYU Counseling Center for the final HRV measurement.
Similar to the baseline HRV measurement, participants from the three groups were asked
to fill out an online survey first and then breathed with their normal breathing rate for 10 minutes.
Data were recorded through the biofeedback system. After that, participants were debriefed.
Total time commitment for the follow-up HRV measurement was approximately 30 minutes
including hooking up electrodes and potential technical problems to resolve. Hence, the total
time commitment for the presented study was approximately 6 weeks.
Imaging Data Processing and Analysis
Imaging data preprocessing and analysis was performed using the Analysis of Functional
Neuroimages (AFNI) software (Cox, 1996). All participants’ functional images were slice-time
corrected. This was done to adjust for shifting in hemodynamic response in adjacent voxels due
to acquisition time difference. Motion correction was performed next to realign the functional
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time courses to their own first image. The processed images were smoothed and blurred across
adjacent voxels to maximize functional signal-to-noise ratio. The structural scan was coregistered to the functional data in order to match functional orientation. Next, participants’
structural scans were aligned through their anterior and posterior commissures (AC-PC).
All participants’ structural and functional scans were normalized to the Talairach atlas
(Talairach & Tournoux, 1988). Advanced Normalization Tools (ANTs, version 1.9,
http://sourceforge.net/projects/advants; Klein et al., 2009; Motley & Kirwan, 2012)
transformation was performed to create a template based on participants’ structural scans. Next,
bilateral ROIs were identified on the ANTs template and back-transformed to individual subject
space. Effects of no interest were identified and removed from the functional time series.
Functional time-series data were then extracted from each ROI and the pair-wise correlations
were calculated between each ROI’s time-series data. Resulting Pearson correlations were ztransformed and then entered into group-level repeated measure analyses of variance (ANOVA)
analyses.
Analytic Strategy
All data were subjected to a 3 (Exp, TAU, Ch ) × 2 (baseline, follow-up time-point)
repeated measure ANOVA design. Dependent variables were the total BDI-II scores, total OQ45
scores, HRV variables, and resting-state connectivity among the ROIs. Separate repeated
measure ANOVA was conducted for each dependent variable. Repeated measure ANOVA was
preformed because there were two categorical groups in the independence variables: three
randomized groups (Exp, TAU, Ch ) and two time points conditions (baseline, follow-up) in the
experiment. This 3 x 2 repeated measure ANOVA design allowed us studying the interaction
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between various experimental groups and conditions by conducting a post-hoc Tukey test.
Furthermore, effect size was measure by partial eta squared (η2).
Results
Baseline Comparison
Psychological measures. Descriptive statistics showed that participants from Exp and
TAU groups scored higher in both total BDI-II and total OQ45 scores in comparison with Ch
group at baseline (see Table 1). Results from repeated measure ANOVAs revealed groups
differences in total BDI-II scores (F(2, 27) = 14.65; p < .001; partial η2 = .52; see Table 2) and
total OQ45 scores (F(2, 27) = 11.26; p = < .001; partial η2 = .45; see Table 2). In specific, results
from post-hoc Tukey test showed no significant differences between Exp’s and TAU’s total
BDI-II scores (Exp M = 24.90; TAU M = 17.70; p = .31; see Table 1) and total OQ45 scores
(Exp M = 84.20; TAU M = 71.10; p = .74; see Table 1) at baseline. Both groups reported mild to
moderate level of depression, scoring above the cutoff for clinically significant levels of distress.

Table 1
Summary of Demographic and Psychological Measures (Mean, Standard Deviation, and Range) by
Groups at Baseline.

N
Age (years)
Range
BDI-IId
Range
e
OQ45
Range

Expa
10
20.09 (1.81)
18.0 – 23.0
24.90 (11.84)
11.0 – 49.0

TAUb
10
20.20 (1.47)
18.0 – 23.0
17.70 (7.10)
2.0 – 28.0

84.20 (26.02)
46.0 – 129.0

71.10 (19.96)
22.0 – 89.0

Chc
10
20.64 (1.29)
18.0 – 23.0
3.70 (3.98)
0.0 – 12.0
32.5 (20.32)
0.0 – 70.0

Note. aExperimental group. bTreatment as usual group. cHealthy control group. dBeck Depression Inventory-II (Beck,
Steer, & Brown, 1996). eThe Outcome Questionnaire-45 (Lambert, Lunnen, Umphress, Hansen, & Burlingame,
1994).
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Table 2
Repeated Measures Analysis of Variance (ANOVA) by Groups for Psychological and Physiological
Measures.

BDI-IIa
OQ45b
SDNNc
Log10LFd
Log10HFe
Log10LF/ Log10HF

Groups
Time
Time*Groups
Groups
Time
Time*Groups
Groups
Time
Time*Groups
Groups
Time
Time*Groups
Groups
Time
Time*Groups
Groups
Time
Time*Groups

df
2
1
2
2
1
2
2
1
2
2
1
2
2
1
2
2
1
2

MS
1291.5
646.8
174.6
8895.7
1706.7
893.3
275.1
398.8
562.9
0.3
0.4
0.4
0.8
0.2
0.1
0.1
0.2
0.03

F
14.65
21.34
5.76
11.26
13.87
7.26
0.45
5.29
7.46
1.55
4.78
4.83
1.75
1.99
0.82
2.16
10.50
2.56

p
< .001
< .001
0.008
< .001
0.001
0.003
0.645
0.029
0.003
0.231
0.038
0.016
0.192
0.170
0.451
0.135
0.003
0.096

partial η2f
0.52
0.44
0.30
0.45
0.34
0.35
0.03
0.16
0.36
0.11
0.16
0.27
0.11
0.07
0.06
0.14
0.29
0.16

Note. aBeck Depression Inventory-II (Beck, Steer, & Brown, 1996). bThe Outcome Questionnaire-45 (Lambert,
Lunnen, Umphress, Hansen, & Burlingame, 1994). cStandard deviation of normal-to-normal intervals. dLow
frequency. eHigh frequency. fPatial eta-squared.

Responses from these two groups suggested that they were admitting to a large number of
distress symptoms, as well as difficulties in their general quality of life. Significant differences
were found between depressed participants’ and healthy controls’ total BDI-II scores and total
OQ45 scores. Both the Exp and TAU groups reported higher depression level and clinically
significant overall distress symptoms than the healthy controls. Participants from the control
group reported a minimal level of depression; their total OQ45 scores were below the clinical
cutoff for distress (total BDI-II scores: Exp M = 24.90; TAU M = 17.70; Ch M = 3.70; p < .001;
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see Table 1; total OQ45 scores: Exp M = 84.20; TAU M = 71.10; Ch M = 32.50; p < .001; see
Table 1).
Physiological measures. Since measures of physiological variables demonstrated
skewed distributions, a logarithm (log10) transformation was performed on the following HRV
variables (LF, HF, LF/HF ratio) before a series of repeated measure ANOVAs were conducted to
evaluate whether the groups (Exp, TAU, Ch) differed with regards to physiological measures at
baseline. Results from repeated measure ANOVAs revealed no significant differences between
groups for SDNN (F(2, 27) = 0.45; p = .645; partial η2 = .03; see Table 2), log10 LF (F(2, 26) =
1.55; p = .231; partial η2 = .11; see Table 2), log10 HF (F(2, 27) = 1.75; p = .192; partial η2 = .11;
see Table 2), and log10 LF/ log10 HF ratio (F(2, 26) = 2.16; p = .135; partial η2 = .14; see Table 2)
at baseline. Participants from all three groups had similar physiological measures at baseline.
Imaging data. Next, another series of repeated measure ANOVAs were performed to
evaluate whether the groups (Exp, TAU, Ch) differed with regard to resting-state connectivity
between each ROIs. Findings from repeated measure ANOVAs showed no significant
differences between groups for all ipsilateral and bilateral ROIs at baseline (see Table 3). Overall,
all three groups of participants had a similar level of resting-state connectivity at baseline.
Details descriptive statistics (mean and standard deviation) for all ROIs at baseline was showed
in Table 4.

Table 3
Repeated Measures Analysis of Variance (ANOVA) by Groups Between Each ROIsa.

L ACC – L Hipp

Groups
Time
Time*Groups

df
2
1
2

MS
2.02
1.87
0.03

F
1.75
1.61
0.03

p
0.185
0.210
0.973

partial η2b
0.07
0.03
0.00
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L ACC – L Amyg
L Hipp – L Amyg
R ACC – R Hipp
R ACC – R Amyg

R Hipp – R Amyg
L ACC – R ACC

L Hipp – R Hipp

L Amyg – R Amyg

Groups
Time
Time*Groups
Groups
Time
Time*Groups

df
2
1
2
2
1
2

MS
1.71
1.61
0.02
1.39
2.05
0.01

F
1.53
1.43
0.02
1.21
1.78
0.01

p
0.227
0.237
0.980
0.306
0.188
0.990

partial η2b
0.06
0.03
0.00
0.05
0.04
0.00

Groups
Time
Time*Groups
Groups
Time

2
1
2
2
1

Time*Groups
Groups
Time
Time*Groups
Groups
Time
Time*Groups
Groups
Time

2
2
1
2
2
1
2
2
1

1.99
1.57
0.02
2.05
1.64
0.01
1.77
1.90
0.08
1.39
1.69
0.17
1.50
2.72

1.58
1.25
0.02
1.81
1.45
0.01
1.55
1.66
0.07
1.19
1.46
0.15
1.13
2.05

0.216
0.270
0.984
0.174
0.235
0.987
0.222
0.204
0.933
0.312
0.133
0.864
0.332
0.159

0.06
0.03
0.00
0.07
0.03
0.00
0.06
0.03
0.00
0.05
0.03
0.01
0.04
0.04

Time*Groups
Groups
Time
Time*Groups

2
2
1
2

0.11
1.32
2.19
0.01

0.08
1.20
1.99
0.01

0.921
0.311
0.165
0.993

0.00
0.05
0.04
0.00

Note. aRegions of interest. bPartial eta-squared. L = left; R = right; ACC = anterior cingulate cortex; Hipp =
hippocampus; Amyg = amygdala.

Table 4
Summary of Correlation Coefficients (Mean, Standard Deviation) by Groups Between Each ROIsa at
Baseline.
Expb
L ACC – L Hipp
L ACC – L Amyg
L Hipp – L Amyg
R ACC – R Hipp
R ACC – R Amyg

0.19
0.16
0.31
0.20
0.10

(0.19)
(0.22)
(0.12)
(0.16)
(0.16)

TAUc
0.75
0.66
0.82
0.73
0.68

(1.53)
(1.42)
(1.44)
(1.57)
(1.44)

Chd
0.12
0.07
0.35
0.15
0.09

(0.15)
(0.13)
(0.19)
(0.12)
(0.09)

p-value
0.185
0.227
0.306
0.216
0.174
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R Hipp – R Amyg
L ACC – R ACC
L Amyg – R Amyg
L Hipp – R Hipp

Expb
0.31 (0.07)
0.65 (0.15)
0.30 (0.13)
0.56 (0.13)

TAUc
0.83 (1.38)
1.11 (1.55)
0.79 (1.41)
0.95 (1.62)

Chd
0.43 (0.16)
0.47 (0.15)
0.35 (0.12)
0.56 (0.13)

p-value
0.222
0.312
0.311
0.332

Note. aRegions of interest. bExperimental group. cTreatment as usual group. dHealthy control group. L = left; R =
right; ACC = anterior cingulate cortex; Hipp = hippocampus; Amyg = amygdala.

Follow-up Comparison
Upon finishing the study, we collected the final psychological, physiological, and
imaging data from all three groups of participants.
Psychological measures. Relative to baseline, inferential statistics showed significant
decreases within the Exp group, but not the TAU or the Ch group, in total BDI-II scores and total
OQ45 scores at the follow-up time point (see Table 5). Results from repeated measure ANOVAs
revealed within-group differences in total BDI-II scores (F(1, 27) = 21.34; p < .001; partial η2
= .44) and total OQ45 scores (F(1, 27) = 13.87; p = .001; partial η2 = .34; see Table 2). Details
from Post-hoc Tukey test on total BDI-II scores showed that the Exp group had a significant
decrease from baseline to the follow-up time point (Mbaseline = 24.90; Mfollow-up = 12.00; p < .001;
see Table 5 and Figure 1). Specifically, Exp group’s depression level dropped from a moderate
to minimal level. Similarly, a post-hoc Tukey test on total OQ45 scores showed a significant
decrease from baseline to the follow-up time point for the Exp group (Mbaseline = 84.20; Mfollow-up
= 59.00; p < .001; see Table 5 and Figure 2). They had a 25-point decrease in their total OQ45
scores at the follow-up time point.
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Table 5
Summary of Psychological Measures (Mean, Standard Deviation) by Groups at Two Time Points.
Baseline

Follow-up

p-value

BDI-IId
OQ45e

24.90 (11.84)
84.20 (26.02)

12.00 (10.28)
59.00 (25.21)

< .001
< .001

TAUb BDI-IId
OQ45e
Ch c
BDI-IId
OQ45e

17.70 (7.10)
71.10 (19.96)

12.10 (5.51)
63.20 (14.44)

0.239
0.610

3.70 (3.98)
32.50 (20.32)

2.50 (3.26)
33.60 (14.71)

0.996
0.999

Expa

Note. aExperimental group. bTreatment as usual group. cHealthy control group. dBeck Depression Inventory-II (Beck,
Steer, & Brown, 1996). eThe Outcome Questionnaire-45 (Lambert, Lunnen, Umphress, Hansen, & Burlingame,
1994).
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Figure 1. BDI-II total scores comparison by groups and two time points.
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Figure 2. OQ45 total scores comparison by groups and two time points.

There were not significant differences in depression score change over time between the
TAU and Ch groups TAU group’s depression scores slightly shifted from a mild to minimal
depression level at the follow-up time point while the health controls’ depression scores
remained at the minimal level (TAU’s total BDI-II scores Mbaseline = 17.70; Mfollow-up = 12.10; p
= .239; Ch’s total BDI-II scores Mbaseline = 3.70; Mfollow-up = 2.50; p = .996; see Table 5 and Figure
1). With regard to their overall distress level, no significant differences were observed between
the two time points. TAU group’s OQ45 scores stayed above the clinical cutoff score at the
follow-up time point while the healthy controls’ OQ45 scores stayed below the clinical cutoff
(TAU’s total OQ45 scores Mbaseline = 71.10; Mfollow-up = 63.20; p = .610; Ch’s total OQ45 scores
Mbaseline = 32.50; Mfollow-up = 33.60; p = .999; see Table 5 and Figure 2).
Furthermore, finding from a Post-hoc Tukey test found no significant differences
between Exp and TAU groups’ total BDI-II scores at the follow-up time point; participants from
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both groups reported a minimal level of depression (Exp M = 12.00; TAU M = 12.10; p = .999;
see Table 5 and Figure 1). A similar result was found for Exp and TAU groups’ total OQ45
scores. These two groups of participants did not have a significant difference in their overall
distress level at the follow-up time point (Exp M = 59.00; TAU M = 63.20; p = .997; see Table 5
and Figure 2). Additionally, no statistical differences were observed between the depressed
participants (Exp and TAU) and the Ch group with regard to total BDI-II scores (Exp M = 12.00;
TAU M = 12.10; Ch M = 2.50; p = .084; see Table 5 and Figure 1). A significant difference was
observed between TAU’s and Ch’s total OQ45 scores at the follow-up time point, with
participants from the TAU group reporting a higher level of overall distress; no difference was
found between Exp and Ch groups’ overall distress level (TAU M =63.20; Exp M = 59.00; Ch M
= 33.60; p = .110; see Table 5 and Figure 2). Both Exp and Ch groups reported an overall distress
level below the clinical cutoff.
Physiological measures. Findings from repeated measure ANOVAs revealed a
significant within-group difference for SDNN (F(1, 27) = 5.29; p = .029; partial η2 = .16; see
Table 2), log10 LF (F(1, 26) = 4.78; p = .038; partial η2 = .16; see Table 2), and log10 LF/ log10 HF
ratio (F(1, 26) = 10.5; p = .003; partial η2 = .29; see Table 2) at the follow-up time point. Further
analysis from post-hoc Tukey test showed that participants from the Exp group demonstrated
17.39 points increase for SDNN from baseline to the follow-up time point (Mbaseline = 42.93;
Mfollow-up = 60.33; p = .002; see Table 6 and Figure 3). The Exp group also showed 0.48 points
increase for log10 LF (Mbaseline = 2.74; Mfollow-up = 3.22; p = .009; see Table 6 and Figure 4) and
0.21 points increase for log10 LF/ log10 HF ratio (Mbaseline = 1.08; Mfollow-up = 1.29; p = .011; see
Table 6 and Figure 6) between the two time points. All of these increases were statistically
significant. However, no significant difference was observed for the Exp group with regard to
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log10 HF; their log10 HF values remained at a similar level relative to baseline (Mbaseline = 2.56;
Mfollow-up = 2.59; p = .999; see Table 6 and Figure 5). In addition, no significant differences were
found for the TAU and Ch groups across all of the physiological variables from baseline to the
follow-up time point. Results for SDNN, log10 LF, log10 HF, and log10 LF/ log10 HF ratio
remained at the similar level for these two groups (see Table 6).

Table 6
Summary Physiological Measures (Mean, Standard Deviation) by Groups at Two Time Points.
Baseline

Expa

Follow-up

p-value

SDNNd
Log10LFe
Log10HFf
Log10LF/ Log10HF

42.93
2.74
2.56
1.08

(23.07)
(0.58)
(0.68)
(0.11)

60.33
3.22
2.59
1.29

(26.54)
(0.35)
(0.58)
(0.25)

0.002
0.009
0.999
0.011

TAUb SDNNd
Log10LFe
Log10HFf
Log10LF/ Log10HF

50.00
2.97
3.02
1.00

(12.13)
(0.30)
(0.39)
(0.20)

48.51
2.91
2.82
1.03

(10.21)
(0.31)
(0.46)
(0.23)

0.998
0.998
0.644
0.995

Ch c

56.74
3.15
2.98
1.07

(16.47)
(0.33)
(0.42)
(0.18)

56.32
3.21
2.84
1.15

(17.87)
(0.37)
(0.48)
(0.19)

0.999
0.997
0.874
0.703

SDNNd
Log10LFe
Log10HFf
Log10LF/ Log10HF

Note. aExperimental group. bTreatment as usual group. cHealthy control group. dStandard deviation of normal-tonormal intervals. e Low frequency. fHigh frequency.

Imaging data. Similar to findings from baseline comparison, results from repeated
measure ANOVAs did not show any significant differences between or within groups from all
ipsilateral and bilateral ROIs at the follow-up time point (see Table 3). Furthermore, no
interaction was observed across all comparisons (see Table 3).
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Figure 3. SDNN (ms) comparison by groups and two time points.
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Figure 4. Log10 LF (ms2) comparison by groups and two time points.

29
3.5
3

Log10 HF (ms²)

2.5
2

Ch
Exp

1.5

TAU

1
0.5
0

Baseline

Follow-up

Figure 5. Log10 HF (ms2) comparison by groups and two time points.
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Figure 6. Log10 LF/ Log10 HF ratio comparison by groups and two time points.
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Discussion
Main Findings
Since major depressive disorder (MDD) is one of the most common psychiatric illnesses
in our society and causes different levels of disturbances in daily functioning (Oquendo et al.,
2006), the current research sought to better understand the efficacy of an adjunct therapy option,
heart-rate variability (HRV) training, for MDD and its impact on participants’ resting-state
connectivity. Upon finishing 5 weeks of HRV training in conjunction with traditional
psychotherapy, we expected the experimental group would show significant changes in their
overall distress level and depression scores between baseline and the follow-up time point. As
expected, there were significant decreases in their overall distress level and depression scores.
Specifically, the experimental group showed a 25-point decrease in their total OQ45 scores
between the two time points. According to Lambert et al. (2004), any changes in the total OQ45
score equal or greater than 14 points are considered to be a reliable and significant change. With
regard to the experimental group’s depression scores, a change from a moderate to minimal
depressed level was observed. Overall, we found significant improvements in the experiment
group’s overall distress level and depression scores at the follow-up time point after controlling
for their baseline level.
Several recent studies of HRV for the treatment of major depression found similar results
(Karavidas et al., 2007; Siepmann et al., 2008). These previous studies also used the total BDI-II
score (Beck et al., 1996) to examine changes in depression levels before and after their
experiments. Results from these previous studies found that depressed participants had a
significantly decreased total BDI-II score after 6 to 10 weeks of HRV biofeedback training
sessions. Together, results from the current study supported findings from existing research that
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HRV training appear to be an efficacious adjunct treatment for reducing depression symptoms
and the overall distress level. Furthermore, findings from the current study showed that the
experimental group was significantly less distressed than the treatment as usual group at the
follow-up time point. In fact, the experimental group’s overall distress level had dropped to a
similar level to that of the healthy control group. Existing research on HRV biofeedback and
depression has mainly used two comparison groups (depressed individuals verses healthy
controls) across different age groups and demographics (Kemp et al., 2012; Patron et al., 2012;
Siepmann et al., 2008; Tonhajzerova et al., 2009). The current research added a new piece of
information in comparing depressed individuals who went through HRV biofeedback training in
conjunction with traditional psychotherapy verses those who only received psychotherapy.
Besides a reduction in psychological symptoms, we also expected the experimental group
would show a significant increase in HRV functioning between the baseline and follow-up time
points. Controlling for baseline levels, significant increases were observed for the following
HRV variables at the follow-up time point: standard deviation of normal-to-normal intervals, low
frequency values, and low frequency to high frequency ratio. By contrast, a minimal difference
was noted for high frequency value. The above four variables are common and important
measures in assessing HRV. Results from recent research have shown that increasing standard
deviation of normal-to-normal intervals were associated with better health outcome. Since
activity in both the sympathetic and parasympathetic systems are almost always presented
together, we look at individuals’ activity level between these two systems in a continuum. Low
frequency values are in between the two spectrums, influencing by both the sympathetic and
parasympathetic system. Lower low frequency values reflected greater influence from the
sympathetic system. High frequency values, on the other hand, reflect parasympathetic activity.
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The higher the high frequency value, the more dominant is the parasympathetic system. Findings
from the experimental group suggest that individuals who went through 5 weekly HRV trainings
have regained more automatic balance between their sympathetic and parasympathetic systems.
A recent study found a similar result where a group of MDD patients demonstrated a significant
increase on standard deviation of normal-to-normal intervals after employing 10 weeks of HRV
breathing training sessions (Karavidas et al., 2007). According to a series of recent studies,
increasing value in standard deviation of normal-to-normal intervals was associated with better
health outcomes (Del Pozo et al., 2004; Karavidas et al., 2007; Patron et al., 2012). Of note,
studies focusing on HRV measurements and depressed population demonstrated that patients
with depression have attenuated HRV (Catipovic-Veselica et al., 2007; Siepmann, Joraschky, &
Rebensburg, 2005).
As noted previously, the experimental group did not show a significant improvement on
high frequency values upon finishing the current study. This finding was in line with a recent
study which involved 6 sessions of HRV biofeedback training over two weeks (Siepmann et al.,
2008). This pervious study did not find a significant change in depressed patients’ high
frequency values after two weeks of HRV training. In addition, their depressed patients’ low
frequency values and low frequency to high frequency ratio did not differ significantly from
baseline to follow up. Interestingly, different from this previous study we found a significant
increase in the experimental group’s standard deviation of normal-to-normal intervals, low
frequency values, and low frequency to high frequency ratio at the follow-up time point. These
differences may be attributed to a longer period of HRV biofeedback training. The previous
study had 6 HRV training sessions over two weeks while the current study had 5 weekly HRV
training sessions. Together, HRV data from the current study suggests that depressed participants
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have learned to increase their HRV by learning and practicing at their resonant frequencybreathing rate.
Apart from the findings above, we also expected that the experimental group would show
a significant increase in resting-state connectivity across all regions of interest (ROIs) between
baseline and the follow-up time point. Contrary to our original prediction, the experimental
group did not have significant changes in resting-state connectivity across each ROIs after 5
weeks of HRV biofeedback training and psychotherapy. In fact, their baseline resting-state
connectivity did not differ from the treatment as usual group and the health control group. These
surprising results may be due to the following factors: participants’ age, number of depression
episodes or depression duration. Research on specific or whole brain resting-state analysis in
major depression has found abnormal functional connectivity across difference networks and
regions. Anand et al. (2005) found a decreasing resting-state connectivity between anterior
cingulate cortex and limbic regions in patients with MDD in comparison to healthy controls.
Another study found a significant reduction in depressed patients’ resting-state connectivity in
their prefrontal-limbic areas bilaterally relative to healthy controls (Lui et al., 2011). It was noted
that these previous studies used patients who were in their late 20’s or early 30’s with at least 22
to 193 months of depression duration. In sum, these studies included patients who were older,
with a greater number of depression episodes or longer depression duration in their studies.
Another recent study that used a group of medication-free patients with a recent diagnosis of
major depression and a group of age- and gender-matched controls found abnormal connectivity
within an affective network, a network associated with attention and working memory, and
within ventromedial visual regions in patients with depression (Veer et al., 2010). Once again,
the current study did not show similar results. Two different participants’ demographics were
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noted when comparing the current study with this previous study: gender and age range. The
previous research included both genders that were in their mid-30’s while the current study only
included female participants in early adulthood. Perhaps more and longer episodes of MDD in
people who are older would more likely reveal deceased resting-state connectivity. Furthermore,
the majority of existing research on resting state connectivity and treatment response in MDD
has mostly focused on antidepressant medication and subjects who were in late adulthood
(Andreescu et al., 2013; Dichter, Gibbs, & Smoski, 2015). Further exploration and collection of
imaging data in HRV biofeedback training may broaden our understanding in this new area of
research.
Groups Equivalence at Baseline
In light of establishing a roughly equal baseline condition, we randomized participants
with MDD into either the experimental group or the treatment as usual group. We found group
equivalence between these two groups’ overall distress level, physiological measurement and
resting-state connectivity at baseline, but not their overall depression level. Comparison between
the experimental and treatment as usual groups’ depression level as measured by BDI-II (Beck et
al., 1996) revealed a clinical difference at baseline. Specifically, participants from the
experimental group reported a moderate level of depression whereas participants from the
treatment as usual group reported a mild level of depression. Upon further examination on
participants’ responses, it was noted that four participants from the experimental group expressed
suicidal thoughts or wishes with one indicating high suicidal ideation. Contingency management
had been made with these four participants’ therapist right after the indication of their suicidal
thoughts. The difference in self-harm thoughts may have contributed to the clinical difference on
their BDI-II scores.
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Relative to the depressed participants from both the experimental and treatment as usual
groups, the healthy control group had significantly less distress and depression levels at baseline.
These results were not surprising but were consistent with existing research findings (Liang, Lee,
Chen, & Chang, 2015). Hence, we expected similar results in HRV measurements between the
depressed participants and the healthy controls at baseline. Contrary to our assumption,
participants from both the experimental and treatment as usual groups did not have lower HRV
measurements than the healthy controls across all physiological variables at baseline. These
surprising results may be due to a couple of factors. First, all participants from both experimental
and treatment as usual groups were in their early adulthood with a mean age of 20 years.
Furthermore, all of them were in their first episode of depression. A recent study used a group of
male patients who were in their mid-20’s with first-episode of major depressive disorder also
found similar results when comparing the depressed patients to the healthy controls at baseline
(Liang et al., 2015). This previous study did not observe any differences in their MDD patients’
low frequency and high frequency values from those of the control group at baseline. It was
noted that both the current study and this previous research used participants from a younger age
group who were experiencing their first episode of depression. Perhaps HRV impairments are
less likely to be revealed in a younger age demographic and during an early stage of depression.
Upon further review on literature focusing on HRV and depression, a majority of them
included various comorbidities, longer period of depression, and a wider age range (Carney &
Freedland, 2008; Kemp et al., 2012; Patron et al., 2012). A recent study investigated the
relationship between HRV and depression in a group of MDD patients who were physically
heathy, unmedicated, but had comorbid anxiety disorders (Kemp et al., 2012). These MDD
patients were in their mid-30’s and a majority of them had either generalized anxiety disorder,
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panic disorder or post-traumatic stress disorder. Relative to the control group in this previous
study, the MDD patients showed reduced HRV. Interestingly, the effect size was even larger
among the MDD patients with comorbid anxiety disorders. Another study aimed to examine the
association between depression and HRV in patients after first-time cardiac surgery (Patron et al.,
2012). Compared to the non-depressed patients in this previous study, patients with depression
revealed significantly lower HRV. It was noted that the depressed patients in this previous study
had a mean age of 60. Comparison between the current study and these previous studies suggest
that perhaps a longer depression period, with multiple episodes, and older age would more likely
be associated with greater HRV impairments.
Limitations and Future Directions
There were several limitations in this study: a small sample size from each comparison
group, a very selected population, and the absence of an active experimental condition in the
healthy control group. The current study only included 10 participants for each comparison
group. The small sample size raises concern of low statistical power which reduces chance of
detecting the likelihood of a statistically significant result for a true effect. Furthermore, a small
sample size study may result in overestimating of effect size and low reproducibility of results.
Hence, future studies may need to increase sample size for each comparison group to increase
power in detecting a true effect and to get a better estimate of effect size.
In addition, all participants in the current study were in their young adulthood and had
their first episode of depression. Existing research on HRV training in conjunction with
psychotherapy approach mainly included participants who were older in age and with more
number of depression episodes (Karavidas et al., 2007; Siepmann et al., 2008). Future studies
may consider doing a longitudinal study on this population in order to keep check on their
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overall distress level, depression scores, and resting-state connectivity. In addition, the current
study only included female participants. Future studies may apply the same protocol but focusing
on male participants. Having more information from both genders may help us better understand
whether or not there is a gender difference in HRV functioning and resting-state connectivity.
Due to funding issues, the current study only included one healthy control group who
went through an active control condition. None of the healthy controls received any HRV
biofeedback training. In future studies, researcher may include an active experimental condition
in the heathy control group. Having a group of participants in the control condition who go
through HRV biofeedback training may provide additional insight of the efficacy of HRV
biofeedback training compared to depressed individuals. As previously mentioned, a higher
number of HRV training sessions may also allow researchers to observe the effect of HRV
biofeedback in these two populations.
Beside an additional active healthy control group, future studies may also consider
adding two different comparison groups in the study: a wait list control group and a placebo
group. The wait list control group will allow us to examine if people with MDD get better over
time regardless of treatment effect. Comparisons between the experimental conditions and the
wait list controls may also provide us additional insights regarding biofeedback HRV training
efficacy. In addition to the wait list control group, we may also include a placebo group in the
experimental condition. Participants from this placebo group will receive fake biofeedback
training. Results from this placebo group will allow us to study placebo effect and how such
effect may affect participants’ HRV functioning and self-perceived distress and depression levels.
Aside from the future directions mentioned above, the current study may also compare
different psychotherapy approaches in conjunction with HRV biofeedback training, in terms of
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long-term effect of symptom reduction in depression and increased well-being. Numerous
studies and reviews suggest that depressed patients undergoing diverse kinds of psychotherapy
have better outcome than wait-list control and no-treatment patients (Lambert, 2013). Results in
treating depression have shown that most psychotherapies produce similar and substantial effects
and that no single approach has been found to be consistently superior (Emmelkamp, 2013).
Hence, investigating and comparing the enduring effect of different kinds of psychotherapy
approaches with HRV biofeedback training may provide additional insights into depression
treatment efficacy and effectiveness.
Overall, despite the limitations inherent in this pilot study, HRV biofeedback training
demonstrated a decrease in MDD participants’ overall distress level and depression scores and an
increase in heart-rate variability. This approach shows promise as an adjunctive treatment for
depression.
Conclusion
In summary, this is the first study to examine impact of HRV biofeedback training on
depressed population psychologically and neurologically. We utilized three comparison groups
in this study to enhance our understanding. Results only partially followed predictions. HRV
biofeedback training appeared to be able to reduce depressed participants’ overall distress and
depression level and increase their heart-rate variability. However, we did not find a significant
change in their resting-state connectivity. Our findings suggest the need for additional studies on
HRV biofeedback training at different stages of depression and how it might affect participants’
neurologically.
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